ACW FY2026 results and outlook
Released
Released
Announcement PDF
Actinogen Medical Limited ACN 086 778 476
Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000
+61 2 8964 7401 | actinogen.com.au
1
ASX ANNOUNCEMENT
Actinogen FY2026 results – pivotal Alzheimer’s trial results imminent
Sydney, 27 August 2026. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to release
its financial results and annual report for the year ended 30 June 2026.
Highlights – Imminent pivotal trial results in Alzheimer’s disease:
• Pivotal Alzheimer’s disease trial remains on track for topline, final results in November this year following
three positive Independent Data Monitoring Committee (DMC) recommendations, including a confidential
“non-futility” review of unblinded efficacy data in January
• Open-label extension phase of the XanaMIA trial commenced March 2026, with 89% of participants
moving directly to the OLE at the end of the main trial, and a total of 108 now on treatment
• Achieved common understandings with the US FDA and the European Medicines Agency (EMA) on the
pathways to marketing approvals in Alzheimer’s disease (AD), including agreement on the streamlined
design of one further pivotal AD trial of Xanamem 10 mg versus placebo commencing in 2027
• Peer-reviewed depression trial manuscript detailing positive anti-depressant activity published in British
Journal of Psychiatry
• June-end cash balance of $16.7 million provides cash runway beyond Alzheimer’s trial final results to mid-
2027
• Completed manufacture of an additional batch of 10mg Xanamem tablets at Catalent (USA) for use in the
OLE phase of the XanaMIA trial
• Strengthened IP protection through active national phase patent filings with the first national acceptances
received for new patents covering Xanamem treatment of cognitive decline in healthy elderly people and
key manufacturing steps
• Enhanced our relationships with key stakeholders by focusing on the importance and uniqueness of
Xanamem’s brain cortisol control mechanism in AD and our impending pivotal trial data
• Received $7.3 million research and development tax incentive (RDTI) rebate from the Australian Tax Office
relating to the 2025 financial year.
Actinogen CEO, Dr Steven Gourlay said:
“FY2026 has been a defining year for Actinogen. We achieved every major objective we set ourselves,
including timely enrolment of the pivotal XanaMIA Alzheimer’s disease trial and its successful interim efficacy
futility and safety review, securing alignment with both the FDA and EMA on relatively streamlined pathways
to marketing approvals, and establishing a cash runway beyond mid-2027.”
“Xanamem is a leading and unique late-stage oral therapy in clinical development for Alzheimer’s disease with
the potential to become a transformational treatment option for patients and their families living with this
devastating condition. Our key focus is to deliver high-quality pivotal trial results in November while at the same
time planning the future activities needed to get Xanamem approved as soon as possible by regulators."
FY2026 Annual Report
Shareholders are encouraged to review the Company’s 2026 digital annual report released separately to the
ASX today which provides full financial statements and a comprehensive analysis of activities and
Actinogen Medical Limited ACN 086 778 476
Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000
+61 2 8964 7401 | actinogen.com.au
2
achievements for the year ended 30 June 2026, including details supporting the highlights outlined in this
announcement.
The digital annual report is also available in the Recent Annual Reports section under the Our Company tab
of the Company’s website www.actinogen.com.au.
Statutory financial result
The statutory result for the 2026 financial year reflects the Company’s ongoing investment in developing and
advancing its lead molecule Xanamem for the treatment of Alzheimer’s disease.
The Net loss after tax for the twelve months ended 30 June 2026 was $15,379,848 (FY2025: loss of
$14,732,263).
The major expenditure item for the year was Research and development costs of $19,027,365
(FY2025: $12,296,568), primarily relating to clinical trials.
Financial position
At 30 June 2026, the Company had a Cash and cash equivalents balance of $16,734,937 (30 June 2025:
$16,504,230). The Company’s FY2026 R&D tax rebate accrual is $10,817,407, which is expected to be
received in Q2 FY2027.
Outlook
The need for improved Alzheimer’s disease treatments is clear and urgent. Current therapies remain limited
in their effectiveness and safety. The Company believes that Xanamem’s unique mechanism of action, oral
administration and promising safety profile positions it as a potentially important breakthrough therapy for
Alzheimer’s disease, depression and other neurodegenerative and psychiatric diseases.
As we look ahead to FY2027, our three major priorities are clear:
1. Successfully complete the XanaMIA trial and deliver a high-quality final dataset in November
2. Continue preparations for the next phase of regulatory and clinical development
3. Actively pursue strategic partnership opportunities that maximize the value of Xanamem globally.
Actinogen remains committed to proactive management across all aspects of the business to deliver the best
outcomes for patients and value for shareholders.
View this announcement on our InvestorHub: https://investors.actinogen.com.au/link/yan9Ke
ENDS
Investors Media
Dr Steven Gourlay Michael Roberts George Hazim
CEO & Managing Director Communications Media & Public Affairs Australia
P: +61 2 8964 7401 M: +61 423 866 231 M: +61 417 516 262
E. steven.gourlay@actinogen.com.au E. michael.roberts@actinogen.com.au E: georgehazim@mediaaffairs.com.au
Announcement authorised by the Board of Actinogen Medical Limited
Actinogen Medical Limited ACN 086 778 476
Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000
+61 2 8964 7401 | actinogen.com.au
3
About Actinogen Medical
Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and
neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and
detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.
Cognitive function means how a person understands, remembers and thinks clearly. Cognitive functions include memory,
attention, reasoning, awareness and decision-making.
Actinogen is currently developing its lead compound, Xanamem, as a promising new therapy for Alzheimer’s Disease. It
has also conducted a phase 2 trial in patients with cognitive impairment and depression and may study Fragile X Syndrome
and other neurological and psychiatric diseases in the future. Reducing cortisol inside brain cells could have a positive
impact in these and many other diseases. The cognitive dysfunction, behavioural abnormalities, and neuropsychological
burden associated with these conditions is debilitating for patients, and there is a substantial unmet medical need for new
and improved treatments.
Clinical Trials
The XanaMIA Phase 2b/3 Alzheimer’s disease trial is a double-blind, 36-week treatment, placebo-controlled, parallel
group design trial in 247 patients with mild to moderate AD and progressive disease, determined by clinical criteria and
confirmed by an elevated level of the pTau181 protein biomarker in blood. Patients receive Xanamem 10 mg or placebo,
once daily, and its ability to slow progression of Alzheimer’s disease is assessed with a variety of endpoints. The primary
endpoint of the trial is the internationally-recognized CDR-SB (Clinical Dementia Rating scale – Sum of Boxes). The trial
is being conducted in Australia and the US and is now closed to participant recruitment. It has passed an independent
Data Monitoring Committee safety and efficacy futility review and final topline results are expected in November 2026.
The XanaMIA-OLE Alzheimer’s disease open-label extension is an open-label phase of up to 25 months treatment
where all participants will receive active Xanamem 10 mg once daily. The trial evaluates safety and a limited number of
efficacy endpoints such as the CDR-SB. The trial commenced in March 2026 and is open to all former and current
participants in the XanaMIA Phase 2b/3 trial.
The XanaCIDD Phase 2a depression trial was a double-blind, six-week proof-of-concept, placebo-controlled, parallel
group design trial in 167 patients with moderate, treatment-resistant depression and a degree of baseline cognitive
impairment. Participants were evenly randomized to receive Xanamem 10 mg once daily or placebo, in most cases in
addition to their existing antidepressant therapy, and effects on cognition and depression were assessed. Trial results were
reported in August 2024 and showed clinically and statistically significant benefits on depression symptoms with positive
effects on the MADRS scale (a validated scale of depression symptom measurement) and the PGI-S (a valid patient
reported assessment of depression severity). Cognition improved markedly and to a similar extent in both Xanamem and
placebo groups. The peer-reviewed publication relating to this trial can be accessed for free via this link:
https://tinyurl.com/ckm63z63.
About Xanamem (emestedastat)
Xanamem’s novel mechanism is to control elevated levels of cortisol (aka the “stress hormone”) in the brain through the
inhibition of the cortisol synthesis enzyme, 11β-HSD1, without affecting production of cortisol by the adrenal glands which
is essential for the body’s normal functioning. Xanamem is a first-in-class, once-a-day pill designed to deliver high levels
of cortisol control in key areas of the brain related to Alzheimer’s and other diseases such as the hippocampus and frontal
cortex. To view Xanamem’s two-minute Mechanism of Action animation, click here.
Chronically elevated cortisol is associated with progression in Alzheimer’s Disease and excess cortisol is known to be
toxic to brain cells. Cortisol itself is also associated with depressive symptoms and when targeted via other mechanisms
has shown some promise in prior clinical trials. The recent XanaCIDD trial demonstrated clinically and sometimes
statistically significant benefits on depressive symptoms, further validating the cortisol control mechanism for the
Xanamem 10 mg oral daily dose.
The Company has studied 11β-HSD1 inhibition by Xanamem in more than 500 volunteers and patients in eight clinical
trials. Xanamem has a promising safety profile and has demonstrated clinical activity in patients with depression, patients
with biomarker-positive Alzheimer’s disease and cognitively normal volunteers. High levels of target engagement in the
brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study.
Actinogen Medical Limited ACN 086 778 476
Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000
+61 2 8964 7401 | actinogen.com.au
4
Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global
regulatory authority. Xanamem® is a trademark of Actinogen Medical.
Disclaimer
This announcement and attachments may contain certain "forward-looking statements" that are not historical facts; are
based on subjective estimates, assumptions and qualifications; and relate to circumstances and events that have not taken
place and may not take place. Such forward looking statements should be considered “at-risk statements” - not to be relied
upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business,
economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes
and uncertainties) that may lead to actual results being materially different from any forward looking statement or the
performance expressed or implied by such forward looking statements. You are cautioned not to place undue reliance on
these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any
obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to
reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future
performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of
achievement or reasonableness of any forward-looking statements and there can be no assurance or guarantee that any
forward-looking statements will be realised.
ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS
WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP.
Share your feedback
Discover